Notification of the Results of the Phase III Clinical Study of HP-3070 (Transdermal Patch for the Treatment of Schizophrenia) in the U.S.

Published: 1/02/2018
Notification of the Results of the Phase III Clinical Study of HP-3070 (Transdermal Patch for the Treatment of Schizophrenia) in the U.S.
Source: WWW.BUSINESSWIRE.COM

MIAMI--(BUSINESS WIRE)--Hisamitsu Pharmaceutical Co., Ltd. (Headquarters: Tosu City, Saga Prefecture, President and Chief Executive Officer (CEO): Hirotaka Nakatomi (hereinafter "Hisamitsu Pharmaceutical"), in conjunction with its U.S. subsidiary, Noven Pharmaceuticals, Inc. (hereinafter “Noven Pharmaceuticals”) announces that the transdermal patch for the treatment of schizophrenia (Development

Read more
Related news
Comment